HIF pathway mutations and erythrocytosis

Expert Review of Hematology

Volumn 3, Issue 1, 2010, Pages 93-101

  McMullin, Mary Frances ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Erythrocytosis; Erythropoietin; HIF; Oxygen sensing pathway; Prolyl hydroxylases; Von Hippel Lindau protein

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA;

ERYTHROCYTOSIS; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; HEMATOCRIT; HIF2A GENE; HUMAN; HYPOXIA; PHD2 GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; THROMBOEMBOLISM; VHL GENE;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; ERYTHROPOIETIN; HUMANS; MUTATION; POLYCYTHEMIA; PROCOLLAGEN-PROLINE DIOXYGENASE; SIGNAL TRANSDUCTION;

EID: 77953449943     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.68     Document Type: Review

References (55)

1. Finch CA, Harker LA, Cook JA. Kinetics of the formed elements of human blood. Blood 50, 699-707 (1977).
2. Bain BJ. Normal ranges. In: Blood Cells A Practical Guide. (4th Edition). Blackwell Publishing, Oxford, UK 203 (2006).
3. Johansson PL, Soodabeh S-K, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: a study of patients with polycythaemia vera and apparent polycythaemia. Br. J. Haematol. 129, 701-705 (2005).
4. Percy MJ. Genetically heterogeneous origins of idiopathic erythrocytosis. Hematology 12, 131-139 (2007).
5. Wedzicha JA, Cotes PM, Empey DW et al. Serum immunoreactive erythropoietin in hypoxic lung disease with and without polycythaemia. Clin. Sci. 69, 413-422 (1985).
6. Hudgson P, Pearce JMS, Yeates WK. Renal artery stenosis with hypertension and high haematocrit. BMJ 1, 18-21 (1967).
7. Trimble M, Caro J, Talalla A, Brain M. Secondary erythrocytosis due to a cerebellar hemangioblastoma: demonstration of erythropoietin mRNA in the tumor. Blood 78, 599-601 (1991).
8. Dickerman RD, Pertusi R, Miller J, Zachariah NH. Androgen-induced erythrocytosis: is it erythropoietin? Am. J. Hematol. 61, 153-158 (1999).
9. Wang GL, Jiang B-H, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995).
10. Semenza G. Perspectives on oxygen sensing Cell 98, 281-284 (1999).
11. Semenza G. HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1-3 (2001).
12. Maynard MA, Heng Q, Chung J et al. Multiple splice variants of the human HIF-3a locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J. Biol. Chem. 278, 11032-11040 (2003).
13. Epstein AC, Gleadle JM, McNeill LA et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
14. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
15. Jaakkola P, Mole DR, Tian Y-M et al. Targeting of HIF-a to the von Hippel- Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
16. Ivan M, Kondo K, Yang H et al. HIFa targeted for VHL-mediated destruction by praline hydroxylation: implication for O2 sensing. Science 292, 464-468 (2001).
17. Tanimoto K, Makino Y, Periera T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1a by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19, 4298-4309 (2000).
18. Maxwell PH, Wiesener MS, Chang G-H et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275(1999).
19. Ohh M, Park CW, Ivan M et al. Ubiquitination of hypoxia-inducible factor requires binding to the b-domain of the von Hippel-Lindau protein. Nature Cell. Biol. 2, 423-427 (2000).
20. Schofield C, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat. Rev. 5, 343-354 (2004)
21. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital polycythaemia in Chuvashia. Blood 89, 2148-2154 (1997).
22. Ang SO, Chen H, Hirota K et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythaemia Nat. Genet. 32, 614-621 (2002).
23. Kaelin WG. Von Hippel-Lindau disease. Annu. Rev. Pathol. Mech. Dis. 2, 145-173 (2007).
24. Pastore Y, Jedickova K, Guan Y et al. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. Am. J. Hum. Genet. 73, 412-419 (2003). (Pubitemid 36921004)
25. Percy MJ, McMullin MF, Jowitt SN et al. Chuvash congenital polycythaemia in 4 families of Asian and Western European ancestry. Blood 102, 1097-1099 (2003).
26. Liu E, Percy MJ, Amos CI et al. The worldwide distribution of VHL 598C>T mutation indicated a single founding event. Blood 103, 1937-1940 (2004).
27. Perrota S, Novili B, Ferraro M et al. Von Hippel-Lindau-dependent polycythaemia is endemic on the island of Ischia: identification of a novel cluster. Blood 107, 514-519 (2006).
28. Cario H, Schwarz K, Jorch N et al. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 90, 19-24 (2005)
29. Pastore YD, Jelinek J, Ang S et al. Mutations in the VHL gene in sporadic apparently congenital polycythaemia. Blood 101, 1591-1595 (2003)
30. Bento MC, Chang K-T, Guan Y et al. Congenital polycythaemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica 90, 128-129 (2005).
31. Percy MJ, Jones FGC, Lappin TRJ, McMullin MF. Mutations in the VHL gene are the major identified cause of inherited erythrocytosis. Blood 106, 109a (2005).
32. Percy MJ, Furlow PW, Jones FGC, Lappin TRJ, Lee FS, McMullin MF. Erythrocytosis caused by mutations in the PHD2 and VHL genes. Blood 118, 1069a (2007).
33. Randi ML, Murgia A, Putti MC et al. Low frequency of VHL gene mutations in young individuals with polycythaemia and high serum erythropoietin. Haematologica 90, 689-691 (2005)
34. Gordeuk VR, Prchal JT. Vascular complications in Chuvash polycythaemia. Semin. Thromb. Hemost. 32, 289-294 (2006)
35. Gordeuk VR, Sergueeva AI, Miasnikova GY et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythaemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103, 3924-3929 (2004).
36. Sergueeva AI, Miasnikova GY, Okhotin DJ et al. Elevated homocysteine, glutathione and cysteinylglycine concentrations in patients homozygous for the Chuvash polycythaemia VHL mutation. Haematologica 93, 279-282 (2008).
37. Smith TG, Brooks JT, Balanos GM et al. Mutation of von Hippel-Lindau tumor suppressor and human cardiopulmonary physiology. PLoS Med. 3, 1178-1186 (2006).
38. Hickey MM, Lam JC, Bezman NA et al. von Hippel-Lindau mutation in mice recapitulates Chuvash polycythaemia via hypoxia-inducible factor-2a signaling and splenic erythropoiesis. J. Clin. Invest. 117, 3879-3889 (2007).
39. van Rooijen E, Voest EE, Logister I et al. Zebrafish mutants in the von Hippel- Lindau tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythaemia. Blood 113, 6449-6460 (2009).
40. Percy MJ, Zhao Q, Flores A et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl Acad. Sci. USA 103, 654-659 (2006).
41. Percy MJ, Furlow PW, Beer PA et al. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 110, 2193-2196 (2007).
42. Ladroue C, Carcenac R, Leporrier M et al. PHD2 mutation and congenital erythrocytosis and panaganglioma. N. Engl. J. Med. 359, 2685-2692 (2008).
43. Al-Sheikh M, Moradkhani K, Lopez M et al. Disturbance in the HIF-1a pathway associated with erythrocytosis: Further evidences brought by frameshift and nonsense mutation in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells Mol. Dis. 40, 160-165 (2008).
44. Albiero E, Ruggeri M, Fortuna S et al. Three novel mutations in the prolyl hydroxylase protein 2 gene of the oxygen sensing pathway in patients with isolated erythrocytosis. Haematologica 94(Suppl. 2), 352-353 (2009).
45. Albiero E, Ruggeri M, Finotto S, Rodeghiero F. A new prolyl hydroxylase domain protein 2 mutation in a JAK2 (V617F) positive patient with a familial myeloproliferative disease. Haematologica 94(Suppl. 2), 352-353 (2009).
46. Takeda k, Ho VC, Takeda H, Duan L-H, Nagy A, Fong G-H. Placental but not heart defects are associated with elevated hypoxia-inducible factor a levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 26, 8336-8346 (2006).
47. Takeda K, Aguila HL, Parikh NS et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 11, 3229-13225 (2008).
48. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 11, 3236-3244 (2008).
49. Percy MJ, Furlow PW, Lucas GS et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 335, 52-58 (2008).
50. Perrotta S, Della Ragione F. The HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 338, 1966 (2008).
51. Percy MJ, Beer PA, Campbell G et al. Novel exon 12 mutations in the HIF2a gene associated with erythrocytosis. Blood 111, 5400-5402 (2008).
52. Gale DP, Harten SK, Reid CD et al. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with HIF2a mutation. Blood 112, 919-921 (2008).
53. Martini M, Teofili L, Cenci T et al. A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis. Haematologica 93, 1068-1071 (2008).
54. Furlow PW, Percy MJ, Sutherland S et al. Erythrocytosis-associated HIF-2a mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor praline. J. Biol. Chem. 284, 9050-9058 (2009)
55. Gruber M, Hu C-J, Johnson RS et al. Acute postnatal ablation of HIF-2a results in anemia. Proc. Natl Acad. Sci. USA 104, 2301-2306 (2007).